Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EJ7U
|
|||
| Former ID |
DIB009027
|
|||
| Drug Name |
CPP-115
|
|||
| Synonyms |
GABA aminotransferase inhibitors (oral), Northwestern University/Catalyst Pharmaceutical Partners; Vigabatrin derivatives (oral, neurological diseases), Northwestern University; Vigabatrin derivatives (oral, drug addiction/epilepsy/neuropathic pain), Catalyst Pharmaceutical Partners
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Tourette syndrome [ICD-11: 8A05.00; ICD-10: F95.2] | Phase 2 | [1] | |
| Infantile spasm [ICD-11: 8A62.0] | Phase 1 | [1], [2] | ||
| Substance use disorder [ICD-11: 6C4Z] | Phase 1 | [3], [4] | ||
| Company |
Catalyst pharmaceutical partners
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C7H9F2NO2
|
|||
| Canonical SMILES |
C1C(CC(=C(F)F)C1N)C(=O)O
|
|||
| InChI |
1S/C7H9F2NO2/c8-6(9)4-1-3(7(11)12)2-5(4)10/h3,5H,1-2,10H2,(H,11,12)/t3-,5-/m0/s1
|
|||
| InChIKey |
CBSRETZPFOBWNG-UCORVYFPSA-N
|
|||
| CAS Number |
CAS 640897-20-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA transaminase (ABAT) | Target Info | Inhibitor | [5] |
| BioCyc | GABA shunt | |||
| Valine degradation | ||||
| Beta-alanine degradation | ||||
| 4-aminobutyrate degradation | ||||
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| Valine, leucine and isoleucine degradation | ||||
| beta-Alanine metabolism | ||||
| Propanoate metabolism | ||||
| Butanoate metabolism | ||||
| Metabolic pathways | ||||
| GABAergic synapse | ||||
| Panther Pathway | Aminobutyrate degradation | |||
| Pyrimidine Metabolism | ||||
| Gamma-aminobutyric acid synthesis | ||||
| Pathwhiz Pathway | Aspartate Metabolism | |||
| Glutamate Metabolism | ||||
| Beta-Alanine Metabolism | ||||
| Valine, Leucine and Isoleucine Degradation | ||||
| Propanoate Metabolism | ||||
| WikiPathways | GABA synthesis, release, reuptake and degradation | |||
| Alanine and aspartate metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8284). | |||
| REF 4 | ClinicalTrials.gov (NCT01493596) A Safety, Tolerability and Pharmacokinetic Study of CPP-115. U.S. National Institutes of Health. | |||
| REF 5 | Clinical pipeline report, company report or official report of Catalyst Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.